Rapid Synchronous Type 1 IFN and Virus-specific T cell Responses Characterize First Wave Non-severe SARS-CoV-2 Infections

Effective control of SARS-CoV-2 infection on primary exposure may reveal correlates of protective immunity to future variants, but we lack insights into immune responses before or at the time virus is first detected. We use blood transcriptomics, multiparameter flow cytometry, and T cell receptor (TCR) sequencing spanning the time of incident non-severe infection in unvaccinated virus-naive individuals to identify rapid type 1 interferon (IFN) responses common to other acute respiratory viruses and cell proliferation responses that discriminate SARS-CoV-2 from other viruses. These peak by the time the virus is first detected and sometimes precede virus detection. Cell proliferation is most evident in CD8 T cells and associated with specific expansion of SARS-CoV-2-reactive TCRs, in contrast to virus-specific antibodies, which lag by 1-2 weeks. Our data support a protective role for early type 1 IFN and CD8 T cell responses, with implications for development of universal T cell vaccines.

Citing Articles

Limitations of neutralizing antibody titers in COVID-19 vaccine efficacy trials and a call for additional correlates of protection.

Hwang Y, Min D, Beom Park W Hum Vaccin Immunother. 2025; 21(1):2473795.

PMID: 40051347 PMC: 11901426. DOI: 10.1080/21645515.2025.2473795.

Paucity of viral infection symptoms in patients with immune-mediated inflammatory diseases.

Yalcin Mutlu M, Kleyer A, Kroenke G, Fagni F, Temiz S, Meder C BMJ Open. 2025; 15(1):e088486.

PMID: 39773803 PMC: 11749532. DOI: 10.1136/bmjopen-2024-088486.

SARS-CoV-2 human challenge reveals biomarkers that discriminate early and late phases of respiratory viral infections.

Rosenheim J, Gupta R, Thakker C, Mann T, Bell L, Broderick C Nat Commun. 2024; 15(1):10434.

PMID: 39616162 PMC: 11608262. DOI: 10.1038/s41467-024-54764-3.

Dysfunctional bronchoalveolar effector memory CD8 T cells in tuberculosis-exposed people living with antiretroviral-naïve HIV infection.

Mthembu M, Claassen H, Khuzwayo S, Voillet V, Naidoo A, Spillner J iScience. 2024; 27(11):111137.

PMID: 39563891 PMC: 11575450. DOI: 10.1016/j.isci.2024.111137.

CD4 and CD8 T cells are required to prevent SARS-CoV-2 persistence in the nasal compartment.

Kar M, Johnson K, Vanderheiden A, Elrod E, Floyd K, Geerling E Sci Adv. 2024; 10(34):eadp2636.

PMID: 39178263 PMC: 11343035. DOI: 10.1126/sciadv.adp2636.

References

Swadling L, Diniz M, Schmidt N, Amin O, Chandran A, Shaw E . Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2. Nature. 2021; 601(7891):110-117. PMC: 8732273. DOI: 10.1038/s41586-021-04186-8. View

Hayward A, Wang L, Goonetilleke N, Fragaszy E, Bermingham A, Copas A . Natural T Cell-mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. Am J Respir Crit Care Med. 2015; 191(12):1422-31. PMC: 4476562. DOI: 10.1164/rccm.201411-1988OC. View

Weight C, Venturini C, Pojar S, Jochems S, Reine J, Nikolaou E . Microinvasion by Streptococcus pneumoniae induces epithelial innate immunity during colonisation at the human mucosal surface. Nat Commun. 2019; 10(1):3060. PMC: 6635362. DOI: 10.1038/s41467-019-11005-2. View

Oakes T, Heather J, Best K, Byng-Maddick R, Husovsky C, Ismail M . Quantitative Characterization of the T Cell Receptor Repertoire of Naïve and Memory Subsets Using an Integrated Experimental and Computational Pipeline Which Is Robust, Economical, and Versatile. Front Immunol. 2017; 8:1267. PMC: 5643411. DOI: 10.3389/fimmu.2017.01267. View

Pairo-Castineira E, Clohisey S, Klaric L, Bretherick A, Rawlik K, Pasko D . Genetic mechanisms of critical illness in COVID-19. Nature. 2020; 591(7848):92-98. DOI: 10.1038/s41586-020-03065-y. View

Manisty C, Treibel T, Jensen M, Semper A, Joy G, Gupta R . Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection. EBioMedicine. 2021; 65:103259. PMC: 7920816. DOI: 10.1016/j.ebiom.2021.103259. View

Sandalova E, Laccabue D, Boni C, Tan A, Fink K, Ooi E . Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PLoS Pathog. 2010; 6(8):e1001051. PMC: 2924358. DOI: 10.1371/journal.ppat.1001051. View

Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A . BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics. 2005; 21(16):3439-40. DOI: 10.1093/bioinformatics/bti525. View

Gupta R, Rosenheim J, Bell L, Chandran A, Guerra-Assuncao J, Pollara G . Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. Lancet Microbe. 2021; 2(10):e508-e517. PMC: 8260104. DOI: 10.1016/S2666-5247(21)00146-4. View

10.

Leek J, Johnson W, Parker H, Jaffe A, Storey J . The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012; 28(6):882-3. PMC: 3307112. DOI: 10.1093/bioinformatics/bts034. View

11.

Treibel T, Manisty C, Andiapen M, Pade C, Jensen M, Fontana M . Asymptomatic health-care worker screening during the COVID-19 pandemic - Authors' reply. Lancet. 2020; 396(10260):1394-1395. PMC: 7598568. DOI: 10.1016/S0140-6736(20)32211-X. View

12.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

13.

Uddin I, Joshi K, Oakes T, Heather J, Swanton C, Chain B . An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood. Methods Mol Biol. 2018; 1884:15-42. DOI: 10.1007/978-1-4939-8885-3_2. View

14.

Wilkinson T, Li C, Chui C, Huang A, Perkins M, Liebner J . Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012; 18(2):274-80. DOI: 10.1038/nm.2612. View

15.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

16.

Pollara G, Murray M, Heather J, Byng-Maddick R, Guppy N, Ellis M . Validation of Immune Cell Modules in Multicellular Transcriptomic Data. PLoS One. 2017; 12(1):e0169271. PMC: 5207692. DOI: 10.1371/journal.pone.0169271. View

17.

Roe J, Venturini C, Gupta R, Gurry C, Chain B, Sun Y . Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. Clin Infect Dis. 2019; 70(5):731-737. DOI: 10.1093/cid/ciz252. View

18.

Grifoni A, Weiskopf D, Ramirez S, Mateus J, Dan J, Rydyznski Moderbacher C . Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020; 181(7):1489-1501.e15. PMC: 7237901. DOI: 10.1016/j.cell.2020.05.015. View

19.

Nelde A, Bilich T, Heitmann J, Maringer Y, Salih H, Roerden M . SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat Immunol. 2020; 22(1):74-85. DOI: 10.1038/s41590-020-00808-x. View

20.

Peacock T, Heather J, Ronel T, Chain B . Decombinator V4: an improved AIRR compliant-software package for T-cell receptor sequence annotation?. Bioinformatics. 2020; 37(6):876-878. PMC: 8098023. DOI: 10.1093/bioinformatics/btaa758. View